mRNA-4157,Pembrolizumab
Moderna,Merck
['melanoma']
today, reports on clinical trial results presented at #aacr23 that found a personalized mrna cancer vaccine combined with immunotherapy may prolong recurrence-free survival in patients with high-risk melanoma. 
Biotech exec focused on improving human health by enabling the integration of innovative genomic techniques to accelerate the development of precision therapies